NDA 021197 · Emd Serono INC
Cetrotide
Cetrorelix Acetate · Subcutaneous
NovelLast checked: Nov 19, 2026Latest source record: Nov 18, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2000
Aug 11, 2000
Approved uses
1
Original approval plus efficacy supplements
Registered trials
117
27 Phase 3, 6 recruiting
FAERS reports
634
439 serious, 7 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 22, 2025.
INDICATIONS AND USAGE Cetrotide ® (cetrorelix acetate for injection) is indicated for the inhibition of premature LH surges in women undergoing controlled ovarian stimulation.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
2 products under this application
- CETROTIDE · CETRORELIX ACETATE EQ 3MG BASE/VIAL · POWDER, SUBCUTANEOUS · Discontinued
- CETROTIDE · CETRORELIX ACETATE EQ 0.25MG BASE/VIAL · POWDER, SUBCUTANEOUS · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Cetrorelix" as an intervention, any sponsor and status, largest first.
- Effectiveness of Generic Versus Reference Cetrorelix Acetate for Ovarian Stimulation Using a Gonadotropin-releasing Hormone(GnRH)Antagonist Protocol in Women Undergoing IVFPivotal-lookingRecruiting
Northwest Women's and Children's Hospital, Xi'an, ShaanxiAcademic, hospital or other
NCT06023602 · 1,338 participants (planned) · Start Feb 27, 2024 · Primary completion Dec 1, 2025
Drug: Generic cetrorelix acetate; Reference cetrorelix acetate · For: Infertility
Sites: Xi'an, China
The First Affiliated Hospital of Zhengzhou UniversityAcademic, hospital or other
NCT02496754 · 1,266 participants · Start Jun 2016 · Primary completion Dec 2022
Drug: GnRH-a; GnRH-anta · For: Clinical Pregnancy Rate; Ovulation Induction; IVF
Sites: Zhengzhou, China
- Letrozole in Stimulated IVF CyclesPivotal-lookingCompleted
The University of Hong KongAcademic, hospital or other
NCT02912988 · 900 participants · Start Mar 1, 2018 · Primary completion Apr 30, 2022
Drug: Letrozole · For: Subfertility
Sites: Hong Kong, China; Beijing, China
- Live Birth Rate Between PPOS and GnRH Antagonist Protocol in Patients With Anticipated High Ovarian ResponsePivotal-lookingCompleted
ShangHai Ji Ai Genetics & IVF InstituteAcademic, hospital or other
NCT04414761 · 784 participants · Start Jun 4, 2020 · Primary completion Oct 10, 2022
Drug: Progesterone; GnRH Antagonist · For: IVF; GnRH Antagonist; PPOS
Sites: Shanghai, China
- Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)Pivotal-lookingTerminated
AEterna ZentarisIndustry
NCT00449150 · 667 participants · Start Mar 2007 · Primary completion Jun 2009
Drug: Cetrorelix 78 mg + 78 mg; Cetrorelix 78 mg + 52 mg and 1 more · For: Benign Prostatic Hypertrophy
Sites: Huntsville, Alabama; Fort Smith, Arkansas; Laguna Hills, California · 68 sites in all
- PPOS vs GnRH Antagonist in Ovarian Stimulation (ProGanOS Study)Pivotal-lookingActive, not recruiting
Mỹ Đức HospitalAcademic, hospital or other
NCT06378268 · 626 participants (planned) · Start Apr 24, 2024 · Primary completion Jun 30, 2026
Drug: Dydrogesterone 10 mg; Cetrorelix 0.25 mg · For: Progestins Primed Ovarian Stimulation
Sites: Ho Chi Minh City, Vietnam
- Cetrotide Treatment OptimizationPivotal-lookingTerminated
Bart CJM FauserAcademic, hospital or other
NCT00866034 · 617 participants · Start Feb 2009 · Primary completion Oct 2012
Drug: Cetrotide (Ovarian stimulation); Cetrotide (Ovarian stimulation) · For: In Vitro Fertilization; Intracytoplasmic Sperm Injection
Sites: Utrecht, Netherlands
- Use of Antagonist Versus Agonist GnRH in Oocyte Recipient Endometrium PreparationPivotal-lookingCompleted
Instituto Valenciano de Infertilidad, IVI VALENCIAAcademic, hospital or other
NCT00633347 · 570 participants · Start Jan 2007 · Primary completion Oct 2009
Drug: Antagonist GnRH Cetrotide; Agonist GnRH Acetate Triptoreline · For: Infertility
Sites: Valencia, Spain
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- ovarian hyperstimulation syndrome136
- drug ineffective45
- premature ovulation41
- abortion spontaneous39
- abdominal distension30
- off label use29
- ascites28
- abdominal pain26
- condition aggravated25
- nausea24
- drug interaction21
- generalised tonic-clonic seizure21
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2005 | 2 |
| 2006 | 4 |
| 2007 | 8 |
| 2008 | 6 |
| 2009 | 16 |
| 2010 | 8 |
| 2011 | 17 |
| 2012 | 18 |
| 2013 | 16 |
| 2014 | 14 |
| 2015 | 33 |
| 2016 | 27 |
| 2017 | 55 |
| 2018 | 58 |
| 2019 | 94 |
| 2020 | 58 |
| 2021 | 34 |
| 2022 | 31 |
| 2023 | 32 |
| 2024 | 33 |
| 2025 | 30 |
| 2026 | 40 |
Recalls
1 FDA enforcement reports for this application.
Jun 29, 2020 · Class II · Terminated
Defective Container: Market complaints of missing rubber stoppers from drug vial. Missing rubber stoppers could lead to lack of sterility assurance.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy of GnRH antagonists in the treatment of uterine fibroids: a meta-analysis.
Sánchez Martín MJ, Huerga López C, Cristóbal García I, et al. · Arch Gynecol Obstet 2025 · Meta-Analysis, Review
- Gonadotrophin-releasing hormone antagonists for assisted conception.
Al-Inany HG, Abou-Setta AM, Aboulghar M · Cochrane Database Syst Rev 2006 · Meta-Analysis, Systematic Review
- Treatment of ovarian hyperstimulation syndrome using gonadotropin releasing hormone antagonist: a pilot study.
Hosseini MA, Mahdavi A, Aleyasin A, et al. · Gynecol Endocrinol 2012 · Clinical Trial, Comparative Study
- Mild Versus Conventional Ovarian Stimulation for Poor Responders Undergoing IVF/ICSI.
Siristatidis C, Salamalekis G, Dafopoulos K, et al. · In Vivo 2017 · Randomized Controlled Trial
- Quantitative serial MRI of the treated fibroid uterus.
Munro KI, Thrippleton MJ, Williams AR, et al. · PLoS One 2014 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Evaluation of pretreatment with Cetrotide in an antagonist protocol for patients with PCOS undergoing IVF/ICSI cycles: a randomized clinical trial.
Eftekhar M, Bagheri RB, Neghab N, et al. · JBRA Assist Reprod 2018 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: Emd Serono INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.